Dade Behring goes public
This article was originally published in The Gray Sheet
Executive Summary
Diagnostics firm completes pre-packaged Chapter 11 debt restructuring and enters the public market with a new board of directors Oct. 3. The firm expects to complete Nasdaq registration within six months; common equity initially will be traded over-the-counter, with prices listed in the pink sheets. In August, Dade Behring announced a debt-to-equity swap to cover $1.5 bil. in liabilities for the company, then privately held (1"The Gray Sheet" Aug. 5, 2002, p. 16)...
You may also be interested in...
Dade Behring’s 8% January Stock Advance Builds On 129% Leap In 2003
Dade Behring's focus on growing its clinical lab diagnostics business while reducing debt, combined with a rising profile on Wall Street and plans to enter the high-volume testing category, are buoying the firm's stock price
Dade’s New Dimension: In Hospital Cost-Cutting Environment, Size Matters
Dade Behring anticipates launching a next-generation Dimension integrated chemistry analyzer system in "high-volume" laboratories in 2005, targeting a $5 bil. worldwide market
Dade Behring To Restructure $1.5 Bil. Debt, Become Public Firm
Diagnostics manufacturer Dade Behring hopes to emerge from its Aug. 1 Chapter 11 bankruptcy protection filing as a public company by October